Revolutionizing Cancer Therapies in India

Innovative small molecule candidates targeting Acute and Chronic Myeloid Leukemia, enhancing patient outcomes through advanced research and development.

Learn More

Bharat advanced Therapeutics

Unveiling the Vision Behind

Our Journey Towards Cancer Innovation.

Bharat Advanced Therapeutics (BAT) is a biotechnology company focused on pioneering the development of innovative small-molecule therapies to address unmet needs in oncology. With a strong foundation in science and a commitment to improving patient outcomes, BAT is advancing a robust pipeline of therapies for Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and other cancers.

We are committed to transforming cancer treatment through pioneering small-molecule therapies, significantly improving patient lives across various demographics.

Learn more

Discover Our Journey So Far

BAT is advancing a portfolio of small-molecule candidates at various stages of discovery, preclinical development, and clinical trials.

Legend

AML/CML- Acute/Chronic Myeloid Leukemia; TNBC- Triple-Negative Breast Cancer; LC- Lung Cancer; CC- Colorectal Cancer; PC- Prostate Cancer

Our Innovation – Next-Generation Oncology Therapies

BAT is committed to advancing first-in-class therapies that offer new hope to cancer patients. Our focus is on developing oral treatments that are easy to administer, reduce treatment burden, and offer better outcomes for patients. With expertise in small-molecule drug discovery and clinical development, we are positioning ourselves to deliver solutions that address critical gaps in cancer care.

Our pipeline is designed to address high-priority cancer indications

AML- Acute Myeloid Leukemia
CML- Chronic Myeloid Leukemia
TNBC- Triple-Negative Breast Cancer
LC- Lung Cancer
CC- Colorectal Cancer
PC- Prostate Cancer

Our Lead Candidates

A Close-Up Shot of a Person Taking a Medicine

Oral Therapy for AML & CML: BAT150030

BAT150030 is an oral therapy designed to target both AML and CML. It offers rapid onset of action, high specificity, and has the ability to overcome resistance and relapse issues seen with current treatments. The drug has reached a key milestone in its development, as it enters clinical trials

Learn more

Our Impact

Proven Results and Growth

Drug Candidates at Advanced Stage

1

Cancers Targeted

6

Drug Candidates in Pipeline

3

Cumulative Experience of Team

150 yrs

Our Research Activities

01

Discover New Therapeutics

Creating targeted therapies for various cancers.

02

Drug Development

Robust testing to ensure safety and efficacy.

03

Collaborative Research

Partnering with institutions for groundbreaking studies.

Collaborations

We combine innovative science and dedication to improve cancer outcomes through accessible therapies, revolutionizing patient care in collaboration globally.

Mount Sinai Hospital, New York City, USA

Our core drug candidates have been discovered by Prof. E Prem Kumar Reddy, Director of the Experimental Therapeutics Institute at Mount Sinai Hospital, NYC. This partnership allows us to leverage cutting-edge research from one of the world’s leading medical institutions. Mount Sinai’s contributions have been instrumental in driving innovation, with over $20 million invested in the development of our small-molecule portfolio targeting cancers like AML and CML.

Aragen Life Sciences, Hyderabad, India

BAT has entered into a strategic partnership with Aragen Life Sciences to advance the development of BAT150030, our lead candidate for treating Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML). Through this collaboration, Aragen provides expertise in toxicology studies, clinical trial support, and regulatory submissions. This partnership enables us to navigate the clinical development pathway efficiently and ensure that BAT150030 progresses swiftly towards commercialization, bringing us closer to delivering transformative leukemia treatments.